Open Label Extension for GLYX13-C-202, NCT01684163

Major Depressive Disorder Clinical Trial

Official title:

Phase 2, Open Label Extension for Subjects With Inadequate/Partial Response to Antidepressants During the Current Episode of Major Depressive Disorder Previously Treated With GLYX-13 (Extension of GLYX13-C-202, NCT01684163)

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT02192099
• Other study ID #: GLYX13-C-203
• Status: Terminated
• Phase: Phase 2
• Start date: September 8, 2014
• Est. completion date: November 8, 2018

Study information

• Verified date: November 2019
• Source: Naurex, Inc, an affiliate of Allergan plc
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Examine the safety of long term repeat exposure to GLYX-13 in subjects who participated in GLYX13-C-202.

Description:

Examine the safety of long term repeat exposure to GLYX-13 in subjects who participated in GLYX13-C-202 in an open label extension trial.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 61
• Est. completion date: November 8, 2018
• Est. primary completion date: November 8, 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

1. Participants who have completed 8 weeks of treatment in the preceding study (GLYX13-C-202, NCT01684163.

2. Participants who wish to continue treatment with GLYX-13 after the preceding study.

3. Meets Diagnostic and Statistical Manual, Fourth Edition, Text Revision (DSM-IV-TR) criteria for major depressive disorder (MDD).

4. Female subjects of childbearing potential with a negative serum pregnancy test prior to entry into the study and who are practicing an adequate method of birth control (eg oral or parenteral contraceptives, intrauterine device, barrier, abstinence) and who do not plan to become pregnant during the course of the study. Female subjects may be included without a negative serum pregnancy test if they are surgically sterile or at least 2 years post-menopausal.

5. Clinical laboratory values <2 times the upper limit of normal (ULN) or deemed not clinically significant per the investigator and Naurex medical monitor.

6. Ability to understand the requirements of the study, provide written informed consent, abide by the study restrictions, and agree to return for the required assessments.

7. Based on the investigator and Naurex medical monitor's clinical judgment, subjects with eating disorders, obsessive compulsive disorder (OCD), panic disorder, post-traumatic stress disorder (PTSD), and generalized anxiety disorders secondary to major depressive episodes (MDEs) are permitted.

Exclusion Criteria:

1. Axis I diagnosis of delirium, dementia, dysthymia, amnestic or other cognitive disorder, schizophrenia or other psychotic disorder, bipolar I or II disorder, eating disorder (anorexia or bulimia nervosa), obsessive-compulsive disorder, panic disorder, acute stress disorder, agoraphobia, social phobia, attention-deficit hyperactivity disorder (ADHD), or PTSD.

2. A clinically significant current Axis II diagnosis of borderline, antisocial, paranoid, schizoid, schizotypal, or histrionic personality disorder

3. Experiencing hallucinations, delusions, or any psychotic symptomatology in the current episode; lifetime history of psychosis.

4. Huntington's, Parkinson's, Alzheimer's, Multiple Sclerosis, or a history of seizures or strokes.

5. Currently hospitalized or residing in an in-patient facility during study participation.

6. Substance abuse since the end of participation in GLYX13-C-202, including greater than or equal to 5 units of alcohol per day where 1 unit = ½ pint of beer, 1 glass of wine 4 oz, or 1 oz. of spirits consumed most weeks or in the opinion of the investigator

7. Women who are planning to become pregnant during the course of the study.

8. Allergy or intolerance to current antidepressant or other current medications.

9. Participation in any clinical trial of an investigational product or device within 30 days of enrollment in this trial with the exception of GLYX13-C-202.

10. Positive screen for drugs of abuse: cocaine, marijuana, PCP, ketamine, opioid or other agent that in the opinion of the investigator is being abused

11. Pose current (past 6 months) suicide risk based on administration of the C SSRS and the investigator's clinical judgment.

12. Human immunodeficiency virus (HIV) infection (based on the based on the HIV-1 & HIV-2 antibody screen) or other ongoing infectious disease.

Related Conditions & MeSH terms

• Depression
• Depressive Disorder
• Depressive Disorder, Major
• Major Depressive Disorder

Intervention

Drug:
• Rapastinel (225 mg/450 mg IV administration)
Investigators began treatment in RAP-MD-05 based on the dose level to which the patient was assigned during participation in GLYX13-C-202; patients originally assigned to rapastinel 5 mg/kg received rapastinel 225 mg, and patients originally assigned to rapastinel 10 mg/kg received rapastinel 450 mg. Investigators had the option to decrease the dose level from 450 to 225 mg if a patient experienced an adverse event(s) that the investigator believed may be associated with rapastinel

Locations

Country	Name	City	State
United States	PharmaSite Research, Inc.	Baltimore	Maryland
United States	Office of Psychiatric Research	Birmingham	Alabama
United States	Chicago Research Center	Chicago	Illinois
United States	Lindner Center of HOPE	Mason	Ohio
United States	Woodlands Professional Princeton Medical Institute Building	Princeton	New Jersey
United States	Finger Lake Clinical Research	Rochester	New York
United States	Boston Clinical Trials Inc.	Roslindale	Massachusetts
United States	PRA Health Sciences Phase 2/3 Outpatient & CNS Clinic	Salt Lake City	Utah
United States	Artemis Institute for Clinical Research	San Diego	California
United States	University of Kansas School of Medicine Clinical Trial Unit	Wichita	Kansas

Sponsors (1)

Lead Sponsor	Collaborator
Naurex, Inc, an affiliate of Allergan plc

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The Number of Participants Who Experience an Adverse Event Over the Course of the Study.	An adverse event (AE) was any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. A TEAE was an AE that occurred after receiving the first dose of investigational product or an AE present prior to first dose but increased in severity during the Treatment Period.	48 Months